Abstract 2201: Population attributable fraction of alcohol consumption on cancer incidence in 2020 in the Republic of Korea

Abstract Backgrounds: Alcohol consumption is the Group I carcinogen according to International Agency for Research on Cancer (IARC). In 2009, National Cancer Center Korea reported that 3.0% and 0.5% of total cancer incidence were attributable to alcohol consumption in men and women, respectively. He...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 84; no. 6_Supplement; p. 2201
Main Authors Min, Ye Lin, Park, YounJu, Byoun, Su Jung, Park, Sue_Kyung, Ko, Kwang Pil, Sung, So-Seul, Kim, Na Young, Jung, Keum Ji, Jee, Sun Ha, Cho, Sung-Il, Lim, Min Kyung, Park, Sohee, Park, Eun Young, Woo, Hae Dong, Jung, Kyu-Won, Yun, E Hwa, Kim, Byungmi, Oh, Jin-Kyoung, Choi, Yoonjoo, Park, Bohyun, Seo, Hong Gwan, Choi, Yoon-Jung, Im, Jeong-Soo
Format Journal Article
LanguageEnglish
Published 22.03.2024
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Backgrounds: Alcohol consumption is the Group I carcinogen according to International Agency for Research on Cancer (IARC). In 2009, National Cancer Center Korea reported that 3.0% and 0.5% of total cancer incidence were attributable to alcohol consumption in men and women, respectively. Herein, we estimated population attributable fraction (PAF) of cancer incidence due to alcohol consumption as of 2020. Methods: We organized the Consensus Committee to establish strategy and methodology of PAF estimation. Based on the consensus, cancer sites for PAF estimation were selected according to the IARC List of classification with sufficient evidence in human. PAF was calculated by using Levin’s formula which incorporates exposure prevalence and relative risk (RR). Exposure prevalence was obtained from the Korea National Health and Nutrition Examination Survey (KNHANES) in 2005, assuming that latent period between exposure to alcohol consumption and diagnosis of cancer would be 15 years. Alcohol consumption was defined as non-drinking (<0.1g/day), light (0.1~30g/day), moderate (30~60g/day), and heavy (60~588g/day) drinking according to the definition by World Health Organization. We estimated RRs from the cohort data established by Korean Genome and Epidemiology Study, National Health Examination data provided by National Health Insurance Services, Korean Cancer Prevention Study-II, and KNHANES, while each cohort was linked with Korea Cancer Registry. RRs were estimated by using Cox proportional hazards model adjusted by age group and smoking status. RRs were then meta-analyzed to yield pooled RR by using random-effects model. Results: A total of 4.1% and 1.2% of all cancer incidence were attributable to alcohol consumption in men and women. By cancer sites, 67.1% of esophageal cancer, 23.8% of oral cavity/pharyngeal cancer, 15.1% of laryngeal cancer, 12.0% of colorectal cancer, and 7.9% of liver cancer were attributable to alcohol consumption in men. In women, 54.1% of liver cancer, 10.3% of colorectal cancer, 7.8% of oral cavity/pharyngeal cancer, and 3.6% of breast cancer were due to alcohol consumption. Conclusion: PAF of cancer incidence due to alcohol consumption has increased in 2020 compared to PAF in 2009. As alcohol consumption is an important cause of oral cavity/pharyngeal, esophageal, and laryngeal cancer in men, and liver and breast cancer in women, prevention measures are required to reduce alcohol consumption for cancer prevention in Korea. Citation Format: Ye Lin Min, YounJu Park, Su Jung Byoun, Sue_Kyung Park, Kwang Pil Ko, So-Seul Sung, Na Young Kim, Keum Ji Jung, Sun Ha Jee, Sung-Il Cho, Min Kyung Lim, Sohee Park, Eun Young Park, Hae Dong Woo, Kyu-Won Jung, E Hwa Yun, Byungmi Kim, Jin-Kyoung Oh, Yoonjoo Choi, Bohyun Park, Hong Gwan Seo, Yoon-Jung Choi, Jeong-Soo Im. Population attributable fraction of alcohol consumption on cancer incidence in 2020 in the Republic of Korea [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2201.
ISSN:1538-7445
1538-7445
DOI:10.1158/1538-7445.AM2024-2201